Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital

Tip Ranks
2025.11.20 11:38
portai
I'm PortAI, I can summarize articles.

RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech with a price target of $3.50. Miehm is a 3-star analyst with a 3.9% average return and a 47.97% success rate. H.C. Wainwright’s Patrick Trucchio also issued a Buy rating, while JonesTrading maintained a Hold rating on the stock.

RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $3.50.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Miehm is a 3-star analyst with an average return of 3.9% and a 47.97% success rate. Miehm covers the Healthcare sector, focusing on stocks such as MannKind, Bausch + Lomb Corporation, and Bausch Health Companies.

In addition to RBC Capital, Oncolytics Biotech also received a Buy from H.C. Wainwright’s Patrick Trucchio in a report issued today. However, yesterday, JonesTrading maintained a Hold rating on Oncolytics Biotech (NASDAQ: ONCY).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer